Blood stem cell procurement: Donor safety issues

Bone Marrow Transplantation

Volumn 21, Issue SUPPL. 3, 1998, Pages

  Anderlini, P ^a   Przepiorka, D ^a   Korbling M ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic blood stem cell transplantation; Filgrastim; Normal donors; Recombinant human granulocyte colony stimulating factor (rhG CSF)

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; BONE PAIN; CELL SELECTION; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; FATIGUE; FEVER; GRANULOCYTE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; INSOMNIA; LEUKAPHERESIS; LEUKOCYTOSIS; LEUKOPENIA; LYMPHOCYTE; NAUSEA; ORGAN DONOR; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RHEUMATIC DISEASE; SIDE EFFECT; THORAX PAIN; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA; VERTIGO;

BLOOD DONORS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; SAFETY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031855207     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1415.
2. Russell N, Gratwohl A, Schmitz N. The place of blood stem cells in allogeneic transplantation. Br J Haematol 1996; 93: 747-753.
3. Lane T. Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era. Transfusion 1996; 36: 585-589.
4. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
5. Dreger P, Haferlach T, Eckstein V et al. Filgrastim-mobilised peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87: 609-613.
6. Korbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
7. dim and lymphoid subsets, and possible predictors of engraftment and GVHD. Blood 1995; 86: 2842-2848.
8. Champlin RE. Peripheral blood progenitor cells: a replacement for marrow transplantation? Semin Oncol 1996; 23: 15-21.
9. Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of granulocyte colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590-595.
10. Körbling M, Chan KW, Anderlini P et al. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant 1996; 18: 885-890.
11. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
12. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
13. Caspar CB, Seger RA, Burger J, Gmür J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-2871.
14. Bonilla MA, Dale D, Zeidler C et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutroponias. Br J Haematol 1994; 88: 723-730.
15. Dale DC, Bonilla MA, Davis MW et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496-2502.
16. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. New Engl J Med 1988; 318: 1414-1422.
17. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. New Engl J Med 1992; 327: 28-35: 99-106.
18. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995; 13: 1023-1035.
19. The American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
20. Anderlini P, Przepiorka D, Champlin R, Körbllng M. Biologic and clinical effects of gyanulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819-2825.
21. Wailer CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-283.
22. Anderlini P, Przepiorka D, Lauppe J et al. Stem cell apheresis: results of the MD Anderson collection protocol in 167 normal donors. Blood 1996; 88: 679a (Abstr.).
23. + cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 601-610.
24. Höglund M, Smedmyr B, Simonsson B et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996; 18: 19-27.
25. + progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase-deficient severe combined immunodeficiency patients. Blood 1996; 88: 1104-1112.
26. + peripheral blood cells from healthy adults mobilized by recombinant human granulocyte-stimulating factor. Blood 1994; 84: 2795-2801.
27. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
28. + cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-512.
29. Neupogen. Thousand Oaks. California: Amgen, 1994 (package insert).
30. + cells. Blood 1996; 87: 4903-4909.
31. de Haas M, Kerst JM, van der School C et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effect on circulating neutrophils. Blood 1994; 84: 3885-3894.
32. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Br J Haematol 1989; 74: 1303-1307.
33. Pollmächer T, Korth C, Mullington J et al. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endoloxin in healthy men. Blood 1996; 87: 900-905.
34. Passos-Coelho JL, Bruine HG, Wright SK el al. Large volume Icukapheresis using regional citrate anticoagulation to collect peripheral blood progenitor cells. J Hematother 1995; 4: 11-19.
35. Hillyer CD, Tiegerman KO, Berkman EM: increase in circulating colony-forming units granulocyte-macrophage during large-volume leukapheresis: evaluation of a new cell separator. Transfusion 1991; 31: 327-332.
36. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologie malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
37. Anderlini P, Przepiorka D, Seong D et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996; 94: 155-158.
38. Stroncek D, Clay M, Lennon S et al. Neutropenia following the collection of granulocyte colony-stimulating factor mobilized blood progenitor cell components is due to the collection of progenitor cells. Blood 1996; 88: 396a (Abstr.).
39. Huhn RD, Yurkow EJ, Tushinski R et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 1996; 24: 839-847.
40. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1996; 96: 415-417.
41. Stroncek D, Clay ME, Herr G et al. Blood counts in healthy donors one year following the collection of G-CSF mobilized stem cells and the results of a second mobilization and collection. Transfusion (in press).
42. - progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant 1996; 18: 1073-1079.
43. Martinez C, Urbano-Ispizua A, Rozman C et al. Effects of GCSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996; 72: 269-272.
44. Malachowski ME, Comenzo RL, Hillyer CD et al. Largevolume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992; 32: 732-735.
45. Bandarenko N, Brecher ME, Owen H et al. Thrombocytopenia in allogeneic peripheral blood stem cell collections. Transfusion 1996; 36: 668-669 (letter).
46. + peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132-4138.
47. Diaz MA, Alegre A, Villa M et al. Allogeneic peripheral blood progenitor cell (PBPC) transplantation in children with haematological malignancies. Br J Haematol 1997; 96: 161-164.
48. Anderlini P, Przepiorka D, Lauppe J et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1997; 97: 485-487.
49. Parkkali T, Volin L, Sirén MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant 1996; 17: 433-434.
50. Falanga A, Marchetti M, Oldani E et al. Changes of hemostatic parameters in healthy donors administered G-CSF for peripheral blood progenitor cells (PBPC) collection. Bone Marrow Transplant 1996; 17 (Suppl. 2): S72 (Abstr.).
51. Harada M, Nagafuji K, Fujisaki T et al. G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. J Hematother 1996; 5: 63-71.
52. Shimoda K, Okamuru S, Inaba S et al. Granulocyte colonystimulating factor and platelet aggregation. Lancet 1993; 341: 633 (letter).
53. 53a Avenarius HJ, Freund M, Deinhardt J, Pilowoda H. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets. Ann Hemcitol 1992; 65: 6-9.
54. 53b Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Blol Blood Marrow Transplant 1997; 3: 45-49.
55. Sakamaki S, Matsunaga T, Hirayama Y et al. Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432-1433 (letter).
56. Hasenclever D, Sextro M, Safety of alloPBSCT donors: biometrical considerations on monitoring long-term risks. Bone Marrow Transplant 1996; 17 (Suppl. 2): S28.
57. Gluekman E, Socié G, Guivarch C et al. The long time forgotten HLA identical bone marrow donor: result of a survey on 818 patients. Blood 1996; 88: 612a (Abstr.).
58. Bortin MM, D'Amaro J, Bach FJ et al. HLA associations with leukemia. Blood 1987; 70: 227-232.
59. Freedman MH, Bonilla MA, Boxer L et al. MDS/AML in patients with severe chronic neutropenia (SCN) receiving GCSF. Blood 1996; 88: 448a (Abstr.).
60. Imashuku S, Hibi S, Nakajima F et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2380 (letter).
61. Oilman P, Jackson D, Guild H. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970; 36: 576-585.
62. de Planque MM, Bacigalupo A, Würsch A et al. Long-term follow-up of severe aplastic anemia patients treated with antithymoeyte globulin. Br J Haematol 1989; 73: 121-126.
63. Baer MR, Bernstein SH, Brunetto VL et al. Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 1996; 87: 1484-1489.